---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: PSMA-targeted radioligand therapy"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: PSMA-targeted radioligand therapy. Topics: FDA-approved indication in androgen pathway modulation-resistant prostate cancer, Patient selection by PSMA positron emission tomography, Taxane-naive disease after one ARPI: trial population and crossover, Taxane-naive disease after one ARPI: efficacy versus a change in ARPI, and 6 further topics. 10 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/psma-targeted-radioligand-therapy"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: PSMA-targeted radioligand therapy

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 PSMA-targeted Radioligand Therapy

<a id="topic-2.2.2.1.5-1"></a>

### FDA-approved indication in androgen pathway modulation-resistant prostate cancer

> “PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and”
> “are considered appropriate to delay taxane-based chemotherapy, or”
> “have received prior taxane-based chemotherapy.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

### Patient selection by PSMA positron emission tomography

> “Select patients with metastatic prostate cancer for treatment with PLUVICTO using LOCAMETZ or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

### Taxane-naive disease after one ARPI: trial population and crossover

> “Patients were required to have progressed only once on an ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide).”
> “Patients were considered appropriate for delay of taxane-based chemotherapy by the investigator.”
> “Of patients that were randomized to receive a change in ARPI, 141 patients (60%) crossed over to receive PLUVICTO after confirmation of radiographic disease progression by BICR.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### Taxane-naive disease after one ARPI: efficacy versus a change in ARPI

| Outcome | Lutetium Lu 177 vipivotide tetraxetan | Change in ARPI | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| Radiographic progression-free survival, median months (95% CI) | “9.3 (7, NE)” | “5.6 (4, 6)” | “0.41 (0.29, 0.56)” |
| Overall survival, median months (95% CI) | “24.5 (19.5, 28.9)” | “23.1 (19.6, 25.5)” | “0.91 (0.72, 1.14)” |

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

### Taxane-naive disease after one ARPI: updated radiographic progression-free survival and safety

> “In an updated analysis at the third interim overall survival analysis, the HR for rPFS was 0·49 (95% CI, 0·39–0·61; median rPFS, 11·60 months [95% CI, 9·30–14·19] vs 5·59 [4·21–5·95]).”
> “The incidence of grade 3–5 adverse events was lower with 177 Lu-PSMA-617 vs ARPI change (81/227 [36%] vs 112/232 [48%]; grade 3–4, 80/227 [35%] vs 111/232 [48%]).”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.5-6"></a>

### Disease after ARPI and taxane chemotherapy: overall survival versus best standard of care

| Outcome | Lutetium Lu 177 vipivotide tetraxetan plus best standard of care | Best standard of care | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| Overall survival, median months (95% CI) | “15.3 (14.2, 16.9)” | “11.3 (9.8, 13.5)” | “0.62 (0.52, 0.74)” |

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

### Disease after ARPI and taxane chemotherapy: imaging-based progression-free survival and adverse events

> “177 Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57;”
> “The incidence of adverse events of grade 3 or above was higher with 177 Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.”

Source: [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)

<a id="topic-2.2.2.1.5-8"></a>

### Comparison with cabazitaxel after docetaxel

> “The primary endpoint was a reduction of at least 50% in PSA.”
> “The first endpoint was met (66% vs. 37% for 177Lu–PSMA-617 vs. cabazitaxel, respectively, by intention to treat;”
> “Overall survival was similar between randomly assigned patients in the two groups (19.1 vs. 19.6 months; difference -0.5, 95% CI: -3.7 to 2.7]; p = 0.77)”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.5-9"></a>

### Myelosuppression

> “In the PSMAfore study, Grade 3 or 4 decreased hemoglobin (7%), decreased leukocytes (4.4%), decreased neutrophils (3.5%), and decreased platelets (2.7%) occurred in patients treated with PLUVICTO.”
> “In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets (9%), decreased leukocytes (7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

### Guideline recommendations

> “Offer 177Lu-PSMA-617 to ARPI and docetaxel pre-treated mCRPC patients with one or more metastatic lesions, highly expressing prostate-specific membrane antigen (PSMA) on diagnostic radiolabelled PSMA positron emission tomography/computed tomography (PET/CT) scan and lacking any relevant non-PSMA avid metastases.”
> “Offer 177Lu-PSMA-617 to ARPI pre-treated mCRPC patients with one or more metastatic lesions, highly expressing PSMA (exceeding the uptake in the liver) on diagnostic radiolabelled PSMA PET/CT scan, if not fit for docetaxel.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “Evidence supports the use of 177Lu-PSMA-617 after taxanes and after androgen therapy.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

Additional sources: [Hofman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33581798/); [Hofman et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38043558/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
